Janux Therapeutics Inc (NASDAQ: JANX)’s stock price has dropped by -0.71 in relation to previous closing price of 37.92. Nevertheless, the company has seen a loss of -5.52% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-28 that Janux Therapeutics (JANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is It Worth Investing in Janux Therapeutics Inc (NASDAQ: JANX) Right Now?
The 36-month beta value for JANX is at 4.19. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for JANX is 32.38M, and currently, shorts hold a 9.61% of that float. The average trading volume for JANX on March 29, 2024 was 704.42K shares.
JANX’s Market Performance
The stock of Janux Therapeutics Inc (JANX) has seen a -5.52% decrease in the past week, with a -19.20% drop in the past month, and a 246.37% gain in the past quarter. The volatility ratio for the week is 6.36%, and the volatility levels for the past 30 days are at 9.11% for JANX. The simple moving average for the past 20 days is -7.22% for JANX’s stock, with a 175.26% simple moving average for the past 200 days.
Analysts’ Opinion of JANX
Many brokerage firms have already submitted their reports for JANX stocks, with BTIG Research repeating the rating for JANX by listing it as a “Buy.” The predicted price for JANX in the upcoming period, according to BTIG Research is $62 based on the research report published on March 21, 2024 of the current year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see JANX reach a price target of $100. The rating they have provided for JANX stocks is “Overweight” according to the report published on March 20th, 2024.
Wedbush gave a rating of “Outperform” to JANX, setting the target price at $24 in the report published on April 06th of the previous year.
JANX Trading at 58.79% from the 50-Day Moving Average
After a stumble in the market that brought JANX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.85% of loss for the given period.
Volatility was left at 9.11%, however, over the last 30 days, the volatility rate increased by 6.36%, as shares sank -22.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +296.73% upper at present.
During the last 5 trading sessions, JANX fell by -5.52%, which changed the moving average for the period of 200-days by +189.84% in comparison to the 20-day moving average, which settled at $40.04. In addition, Janux Therapeutics Inc saw 250.89% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JANX starting from Avalon Ventures XI, L.P., who purchase 849,854 shares at the price of $5.87 back on Nov 13 ’23. After this action, Avalon Ventures XI, L.P. now owns 849,854 shares of Janux Therapeutics Inc, valued at $4,988,643 using the latest closing price.
Reardon Tighe, the Acting Chief Financial Officer of Janux Therapeutics Inc, purchase 849,854 shares at $5.87 during a trade that took place back on Nov 13 ’23, which means that Reardon Tighe is holding 849,854 shares at $4,988,643 based on the most recent closing price.
Stock Fundamentals for JANX
Current profitability levels for the company are sitting at:
- -9.03 for the present operating margin
- 0.76 for the gross margin
The net margin for Janux Therapeutics Inc stands at -7.21. The total capital return value is set at -0.2. Equity return is now at value -17.53, with -15.66 for asset returns.
Based on Janux Therapeutics Inc (JANX), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -2.06. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 22.28.
Currently, EBITDA for the company is -71.02 million with net debt to EBITDA at -0.07. When we switch over and look at the enterprise to sales, we see a ratio of 241.29. The receivables turnover for the company is 3.67for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 26.80.
Conclusion
In conclusion, Janux Therapeutics Inc (JANX) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
